Katrina Baren
Payments from drug & device makers
Across 136 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$848
- GSK$261
- AbbVie$213
- Nevro Corp.$192
- Pfizer$101
- Biohaven Pharmaceutical Holding Company Ltd.$96
- plus $535 from 14 others
What the payments were for
- Food & beverage$2,247100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 73 | $848 |
| GSK | 17 | $261 |
| AbbVie | 8 | $213 |
| Nevro Corp. | 9 | $192 |
| Pfizer | 4 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $96 |
| Biodelivery Sciences International, Inc. | 1 | $76 |
| Globus Medical | 2 | $57 |
| Vertex | 2 | $57 |
| Quidel Corporation | 1 | $48 |
| Averitas Pharma Inc. | 1 | $46 |
| Emergent Biosolutions Inc. | 1 | $45 |
| Novartis | 2 | $43 |
| GRT US Holding, Inc. | 3 | $41 |
| Amgen | 2 | $33 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Lucid Diagnostics Inc. | 1 | $20 |
| SPR Therapeutics, Inc | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,247 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 889 | $36,777 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 951 | $25,521 |
| MovantikNaloxegol Oxalate | 25 | $10,149 |
| OxycontinOxycodone Hcl | 32 | $9,537 |
| Gabapentin | 407 | $7,453 |
| Oxycodone Hcl | 310 | $6,585 |
| Morphine Sulfate ErMorphine Sulfate | 143 | $4,335 |
| Lidocaine | 41 | $2,422 |
| Pregabalin | 150 | $2,325 |
| Tramadol Hcl | 335 | $2,314 |
| Cyclobenzaprine Hcl | 196 | $2,182 |
| Tizanidine Hcl | 221 | $1,718 |
| Duloxetine Hcl | 52 | $1,656 |
| Methocarbamol | 122 | $1,601 |
| Ondansetron OdtOndansetron | 62 | $1,281 |
Paid to pharmacies, not to this prescriber.
Other family in Reno
- Lisa Hammargren-KuykendallReno$22K
- Martha AiyukReno$15K
- Jocelyn AllenReno$12K
- Kaylie HumphreysReno$11K
- Christina KrainbrinkReno$10K
- Barbara SzatkowskiReno$10K
- Johanna LeeReno$9K
- Darin OldeReno$9K
- Ruth SkinnerReno$8K
- Anna EllisReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.